| Entry |
|
|---|
| Name |
Olanzapine pamoate (USAN);
Olanzapine pamoate monohydrate;
Zyprexa (TN) |
|---|
| Product |
|
|---|
| Formula |
C23H16O6. C17H20N4S. H2O
|
|---|
| Exact mass |
718.2461
|
|---|
| Mol weight |
718.8173
|
|---|
| Structure |
|
|---|
| Class |
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG01644 CYP2D6 substrate
|
|---|
| Remark |
| Product (DG00898): | D00454<JP/US> D06623<US> |
|
|---|
| Efficacy |
Antipsychotic |
|---|
| Disease |
|
|---|
| Comment |
Multi-acting-receptor-targeting-antipsychotics (MARTA)
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP1A2 [HSA: 1544]; CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07211 | Serotonin receptor agonists/antagonists |
| map07213 | Dopamine receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AH Diazepines, oxazepines, thiazepines and oxepines
N05AH03 Olanzapine
D06623 Olanzapine pamoate (USAN) <US>
USP drug classification [BR:br08302]
Antipsychotics
2nd Generation/Atypical
Olanzapine
D06623 Olanzapine pamoate (USAN)
Bipolar Agents
Bipolar Agents, Other
Olanzapine
D06623 Olanzapine pamoate (USAN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG00898 Olanzapine
D06623 Olanzapine pamoate
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG00898 Olanzapine
D06623 Olanzapine pamoate
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
DG00898 Olanzapine
D06623 Olanzapine pamoate
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
DG00898 Olanzapine
D06623 Olanzapine pamoate
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00898 Olanzapine
D06623 Olanzapine pamoate
DG01644 CYP2D6 substrate
DG00898 Olanzapine
D06623 Olanzapine pamoate
Drug classes [BR:br08332]
Anti-allergic agent
DG01482 Histamine receptor H1 antagonist
D06623 Olanzapine pamoate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1
D06623 Olanzapine pamoate (USAN) <US>
Dopamine
DRD2
D06623 Olanzapine pamoate (USAN) <US>
DRD3
D06623 Olanzapine pamoate (USAN) <US>
DRD4
D06623 Olanzapine pamoate (USAN) <US>
Histamine
HRH1
D06623 Olanzapine pamoate (USAN) <US>
Serotonin
HTR2
D06623 Olanzapine pamoate (USAN) <US>
HTR6
D06623 Olanzapine pamoate (USAN) <US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D06623
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D06623
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG00898 Olanzapine
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG00898 Olanzapine
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
DG00898 Olanzapine
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
DG00898 Olanzapine
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00898 Olanzapine
DG01644 CYP2D6 substrate
DG00898 Olanzapine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 52
1 C8y C 11.3427 -11.7361
2 C8y C 10.4996 -10.6169
3 C8y C 10.8416 -9.2533
4 N4x N 12.1122 -8.6764
5 N5x N 12.7566 -11.7665
6 C8y C 13.3709 -9.3068
7 C8y C 13.6543 -10.6847
8 S2x S 9.6504 -8.5067
9 C8y C 8.5722 -9.4089
10 C8x C 9.0970 -10.6428
11 C1a C 7.2332 -9.0864
12 N1y N 10.6172 -12.9326
13 C8x C 14.9821 -11.1260
14 C8x C 16.0283 -10.1966
15 C8x C 15.7450 -8.8188
16 C8x C 14.4171 -8.3774
17 C1x C 9.2325 -12.9729
18 C1x C 8.5684 -14.2046
19 N1y N 9.3030 -15.3956
20 C1x C 10.6877 -15.4251
21 C1x C 11.3518 -14.1236
22 C1a C 8.6088 -16.6086
23 C8x C 16.8979 -13.3774
24 C8x C 16.8979 -14.7572
25 C8x C 18.0927 -15.4470
26 C8x C 19.2877 -14.7572
27 C8y C 19.2877 -13.3774
28 C8y C 18.0927 -12.6876
29 C8y C 20.4825 -12.6876
30 C8y C 20.4825 -11.3078
31 C8y C 19.2877 -10.6180
32 C8x C 18.0927 -11.3078
33 C1b C 22.3693 -13.5166
34 C8y C 23.9624 -12.6976
35 C8y C 25.1320 -13.3729
36 C8y C 26.3269 -12.6829
37 C8x C 26.3269 -11.3032
38 C8y C 25.1572 -10.6280
39 C8y C 23.9623 -11.3179
40 C8x C 25.1320 -14.7526
41 C8x C 26.3270 -15.4424
42 C8x C 27.5218 -14.7525
43 C8x C 27.5218 -13.3728
44 C6a C 19.2877 -9.2384
45 O6a O 20.5011 -8.5377
46 O6a O 18.1114 -8.5592
47 C6a C 25.1570 -9.2383
48 O6a O 23.9765 -8.5569
49 O6a O 26.3662 -8.5399
50 O1a O 21.6794 -10.6168
51 O1a O 22.7422 -10.6134
52 O0 O 22.8900 -16.5200
BOND 57
1 3 4 1
2 1 5 2
3 4 6 1
4 2 3 2
5 5 7 1
6 1 2 1
7 6 7 1
8 3 8 1
9 8 9 1
10 9 10 2
11 2 10 1
12 9 11 1
13 1 12 1
14 7 13 2
15 13 14 1
16 14 15 2
17 15 16 1
18 6 16 2
19 12 17 1
20 17 18 1
21 18 19 1
22 19 20 1
23 20 21 1
24 12 21 1
25 19 22 1
26 23 24 2
27 24 25 1
28 25 26 2
29 26 27 1
30 27 28 2
31 23 28 1
32 27 29 1
33 29 30 2
34 30 31 1
35 31 32 2
36 28 32 1
37 29 33 1
38 33 34 1
39 34 35 1
40 35 36 2
41 36 37 1
42 37 38 2
43 38 39 1
44 34 39 2
45 35 40 1
46 40 41 2
47 41 42 1
48 42 43 2
49 36 43 1
50 31 44 1
51 44 45 2
52 44 46 1
53 38 47 1
54 47 48 2
55 47 49 1
56 30 50 1
57 39 51 1
|
|---|
